Resumo

DEAZ M, Juan C et al. Peri-operative management of patients with anti-platelet or anticoagulation treatment. Rev. Colomb. Cardiol. [online]. 2012, vol.19, n.5, pp.252-259. ISSN 0120-5633.

Treatment of patients receiving therapies that affect normal hemostasis (anticoagulants and / or anti-platelet aggregators) and that will undergo surgery, is one of the challenges that arise with increasing frequency in the cardiology services. Making the best therapeutic option in these patients requires a thorough understanding of the risks of bleeding in case of continuing the treatment against the risks of thrombosis or embolism in case of stopping it. By tradition, this decision has been based more on fear to the risk of bleeding, whereby in many cases this therapy has been suspended unnecessarily. In recent years, the emergence of evidence indicates that the risk of bleeding is not high and that continuation of these drugs in many cases reduce major adverse outcomes. This has led to redefine this behavior. In this article we review the current evidence available on the subject and provide guidelines that allow making a right decision.

Palavras-chave : anticoagulants; platelet aggregation inhibitors; hemorrhage; thrombosis.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )